STOCK TITAN

[S-8 POS] Vigil Neuroscience, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Qualys (QLYS) Q2-25 10-Q highlights: Revenue rose 10.3% YoY to $164.1 m, marking a sixth straight double-digit quarterly increase. Gross margin remained robust at 82.4% (vs. 82.2% a year ago). Operating income grew 7% to $51.4 m, but opex rose 13%—slightly compressing operating margin to 31.3%. Net income advanced 8% to $47.3 m; diluted EPS climbed 10% to $1.29. For 1H-25, revenue reached $324.0 m (+10%), net income $94.8 m (+13.6%) and operating cash flow $143.4 m (+6%).

Balance sheet & cash flow: Cash and cash equivalents declined $38.2 m sequentially to $194.0 m; however, total liquidity (cash + marketable securities) rose to $468.2 m. Current deferred revenue fell 4% to $355.0 m, while remaining performance obligations total $433.2 m, with 33% recognizable in 2H-25. Share buybacks totaled $89.5 m YTD, reducing shares outstanding to 36.1 m; $254.6 m remains under the $1.4 bn authorization.

Other items: Stock-based compensation was $18.0 m in Q2 (11% of revenue). OCI swung to a $4.2 m loss, mainly from FX hedge valuation. A headquarters lease extension added $30.4 m in future commitments, lifting ROU assets and lease liabilities. No new debt or material litigation disclosed.

Key takeaways: Qualys continues to pair double-digit top-line growth with industry-leading margins and strong cash generation. Deferred-revenue softness and higher operating spend warrant monitoring, but liquidity and buybacks support EPS momentum.

Qualys (QLYS) evidenze del 10-Q del 2° trimestre 2025: I ricavi sono aumentati del 10,3% su base annua, raggiungendo 164,1 milioni di dollari, segnando il sesto trimestre consecutivo con una crescita a doppia cifra. Il margine lordo è rimasto solido al 82,4% (rispetto all'82,2% dell'anno precedente). L'utile operativo è cresciuto del 7%, arrivando a 51,4 milioni di dollari, mentre le spese operative sono aumentate del 13%, comprimendo leggermente il margine operativo al 31,3%. L'utile netto è salito dell'8% a 47,3 milioni di dollari; l'utile per azione diluito è aumentato del 10% a 1,29 dollari. Nel primo semestre 2025, i ricavi hanno raggiunto 324,0 milioni di dollari (+10%), l'utile netto 94,8 milioni (+13,6%) e il flusso di cassa operativo 143,4 milioni (+6%).

Bilancio e flusso di cassa: La liquidità e le disponibilità liquide sono diminuite di 38,2 milioni di dollari rispetto al trimestre precedente, attestandosi a 194,0 milioni; tuttavia, la liquidità totale (contanti + titoli negoziabili) è salita a 468,2 milioni. I ricavi differiti correnti sono scesi del 4% a 355,0 milioni, mentre le obbligazioni residue di prestazione ammontano a 433,2 milioni, con il 33% riconoscibile nella seconda metà del 2025. I riacquisti di azioni hanno totalizzato 89,5 milioni di dollari da inizio anno, riducendo le azioni in circolazione a 36,1 milioni; restano 254,6 milioni disponibili nell'autorizzazione da 1,4 miliardi.

Altri elementi: La remunerazione basata su azioni è stata di 18,0 milioni nel 2° trimestre (11% dei ricavi). L'OCI ha registrato una perdita di 4,2 milioni, principalmente dovuta alla valutazione delle coperture FX. L'estensione del contratto di locazione della sede centrale ha aggiunto 30,4 milioni di impegni futuri, aumentando gli asset e le passività da diritto d'uso. Non sono stati comunicati nuovi debiti né controversie rilevanti.

Punti chiave: Qualys continua a combinare una crescita a doppia cifra dei ricavi con margini leader nel settore e una solida generazione di cassa. La debolezza nei ricavi differiti e l’aumento delle spese operative meritano attenzione, ma la liquidità e i riacquisti supportano la dinamica positiva dell’utile per azione.

Aspectos destacados del 10-Q del 2T-25 de Qualys (QLYS): Los ingresos aumentaron un 10,3% interanual hasta 164,1 millones de dólares, marcando el sexto trimestre consecutivo con un crecimiento de dos dígitos. El margen bruto se mantuvo sólido en 82,4% (frente al 82,2% del año anterior). El ingreso operativo creció un 7% hasta 51,4 millones de dólares, aunque los gastos operativos aumentaron un 13%, comprimiendo ligeramente el margen operativo al 31,3%. La utilidad neta avanzó un 8% hasta 47,3 millones; las ganancias diluidas por acción subieron un 10% hasta 1,29 dólares. En el primer semestre de 2025, los ingresos alcanzaron 324,0 millones (+10%), la utilidad neta 94,8 millones (+13,6%) y el flujo de caja operativo 143,4 millones (+6%).

Balance y flujo de caja: El efectivo y equivalentes disminuyeron 38,2 millones secuencialmente hasta 194,0 millones; sin embargo, la liquidez total (efectivo + valores negociables) aumentó a 468,2 millones. Los ingresos diferidos corrientes cayeron un 4% a 355,0 millones, mientras que las obligaciones de desempeño restantes totalizan 433,2 millones, con un 33% reconocible en el segundo semestre de 2025. Las recompras de acciones sumaron 89,5 millones en lo que va del año, reduciendo las acciones en circulación a 36,1 millones; quedan 254,6 millones disponibles bajo la autorización de 1,4 mil millones.

Otros aspectos: La compensación basada en acciones fue de 18,0 millones en el 2T (11% de los ingresos). El OCI pasó a una pérdida de 4,2 millones, principalmente por la valoración de coberturas cambiarias. Una extensión del contrato de arrendamiento de la sede central añadió 30,4 millones en compromisos futuros, aumentando activos y pasivos por derecho de uso. No se divulgaron nuevas deudas ni litigios materiales.

Conclusiones clave: Qualys sigue combinando un crecimiento de ingresos de dos dígitos con márgenes líderes en la industria y fuerte generación de efectivo. La debilidad en ingresos diferidos y el aumento del gasto operativo merecen seguimiento, pero la liquidez y las recompras respaldan el impulso en las ganancias por acción.

Qualys (QLYS) 2025년 2분기 10-Q 주요 내용: 매출이 전년 대비 10.3% 증가한 1억 6,410만 달러를 기록하며 6분기 연속 두 자릿수 성장세를 이어갔습니다. 총 이익률은 82.4%로 견고하게 유지되었습니다(전년 동기 82.2%). 영업이익은 7% 증가한 5,140만 달러였으나, 영업비용이 13% 증가해 영업이익률은 다소 하락한 31.3%를 기록했습니다. 순이익은 8% 증가한 4,730만 달러, 희석주당순이익(EPS)은 10% 상승한 1.29달러였습니다. 2025년 상반기 매출은 3억 2,400만 달러(+10%), 순이익은 9,480만 달러(+13.6%), 영업현금흐름은 1억 4,340만 달러(+6%)였습니다.

재무상태표 및 현금흐름: 현금 및 현금성 자산은 전분기 대비 3,820만 달러 감소한 1억 9,400만 달러였으나, 총 유동성(현금 + 시장성 증권)은 4억 6,820만 달러로 증가했습니다. 현재 이연수익은 4% 감소한 3억 5,500만 달러이며, 남은 이행 의무는 총 4억 3,320만 달러로 이 중 33%는 2025년 하반기에 인식될 예정입니다. 올해 들어 자사주 매입은 8,950만 달러에 달하며, 유통 주식 수는 3,610만 주로 감소했습니다. 14억 달러 한도 내에서 2억 5,460만 달러가 남아있습니다.

기타 항목: 2분기 주식기반보상은 1,800만 달러(매출의 11%)였습니다. 기타포괄손익(OCI)은 주로 외환 헤지 평가손실로 420만 달러 손실 전환되었습니다. 본사 임대 연장으로 향후 약속금액이 3,040만 달러 추가되어 사용권자산 및 임대부채가 증가했습니다. 신규 부채나 주요 소송은 없었습니다.

주요 시사점: Qualys는 두 자릿수 매출 성장과 업계 선도 마진, 강력한 현금 창출을 지속적으로 조합하고 있습니다. 이연수익의 약세와 운영 비용 증가에 주의가 필요하지만, 유동성과 자사주 매입이 EPS 성장 모멘텀을 뒷받침하고 있습니다.

Faits marquants du 10-Q du 2e trimestre 2025 de Qualys (QLYS) : Le chiffre d'affaires a augmenté de 10,3 % en glissement annuel pour atteindre 164,1 millions de dollars, marquant le sixième trimestre consécutif de croissance à deux chiffres. La marge brute est restée solide à 82,4 % (contre 82,2 % il y a un an). Le résultat d'exploitation a progressé de 7 % pour atteindre 51,4 millions de dollars, mais les charges d'exploitation ont augmenté de 13 %, comprimant légèrement la marge opérationnelle à 31,3 %. Le résultat net a augmenté de 8 % pour atteindre 47,3 millions de dollars ; le BPA dilué a grimpé de 10 % à 1,29 dollar. Pour le premier semestre 2025, le chiffre d'affaires s'est élevé à 324,0 millions (+10 %), le résultat net à 94,8 millions (+13,6 %) et les flux de trésorerie opérationnels à 143,4 millions (+6 %).

Bilan et flux de trésorerie : La trésorerie et les équivalents de trésorerie ont diminué de 38,2 millions séquentiellement pour atteindre 194,0 millions ; toutefois, la liquidité totale (trésorerie + titres négociables) a augmenté pour atteindre 468,2 millions. Les revenus différés courants ont chuté de 4 % à 355,0 millions, tandis que les obligations de performance restantes totalisent 433,2 millions, dont 33 % sont reconnaissables au second semestre 2025. Les rachats d'actions ont totalisé 89,5 millions depuis le début de l'année, réduisant le nombre d'actions en circulation à 36,1 millions ; 254,6 millions restent disponibles dans le cadre de l'autorisation de 1,4 milliard.

Autres éléments : La rémunération à base d'actions s'est élevée à 18,0 millions au 2e trimestre (11 % du chiffre d'affaires). Les autres éléments du résultat global (OCI) sont passés à une perte de 4,2 millions, principalement en raison de la valorisation des couvertures de change. Une extension du bail du siège social a ajouté 30,4 millions d'engagements futurs, augmentant les actifs au titre du droit d’usage et les passifs locatifs. Aucune nouvelle dette ni litige important n'a été divulgué.

Points clés : Qualys continue d’allier une croissance à deux chiffres du chiffre d’affaires à des marges leaders sur le marché et une forte génération de trésorerie. La faiblesse des revenus différés et l’augmentation des dépenses opérationnelles méritent une surveillance, mais la liquidité et les rachats d’actions soutiennent la dynamique du BPA.

Qualys (QLYS) Highlights aus dem 10-Q für Q2-25: Der Umsatz stieg im Jahresvergleich um 10,3 % auf 164,1 Mio. USD und verzeichnet damit das sechste Quartal in Folge mit zweistelligem Wachstum. Die Bruttomarge blieb mit 82,4 % robust (vor einem Jahr 82,2 %). Das Betriebsergebnis wuchs um 7 % auf 51,4 Mio. USD, während die Betriebskosten um 13 % stiegen, was die operative Marge leicht auf 31,3 % drückte. Der Nettogewinn stieg um 8 % auf 47,3 Mio. USD; das verwässerte Ergebnis je Aktie kletterte um 10 % auf 1,29 USD. Für das erste Halbjahr 2025 erreichten die Umsätze 324,0 Mio. USD (+10 %), der Nettogewinn 94,8 Mio. USD (+13,6 %) und der operative Cashflow 143,4 Mio. USD (+6 %).

Bilanz & Cashflow: Zahlungsmittel und Zahlungsmitteläquivalente sanken im Quartalsvergleich um 38,2 Mio. USD auf 194,0 Mio. USD; die Gesamtlquidität (Barmittel + handelbare Wertpapiere) stieg jedoch auf 468,2 Mio. USD. Die kurzfristigen abgegrenzten Erlöse fielen um 4 % auf 355,0 Mio. USD, während die verbleibenden Leistungsverpflichtungen insgesamt 433,2 Mio. USD betragen, von denen 33 % im zweiten Halbjahr 2025 erkennbar sind. Aktienrückkäufe beliefen sich seit Jahresbeginn auf 89,5 Mio. USD und reduzierten die ausstehenden Aktien auf 36,1 Mio.; unter der 1,4 Mrd. USD-Autorisierung verbleiben 254,6 Mio. USD.

Sonstiges: Aktienbasierte Vergütungen betrugen im 2. Quartal 18,0 Mio. USD (11 % der Umsätze). Das sonstige Ergebnis (OCI) drehte in einen Verlust von 4,2 Mio. USD, hauptsächlich aufgrund der Bewertung von Devisenabsicherungen. Eine Verlängerung des Hauptsitzmietvertrags fügte zukünftige Verpflichtungen in Höhe von 30,4 Mio. USD hinzu, was die Nutzungsrechte und Leasingverbindlichkeiten erhöhte. Keine neuen Schulden oder wesentlichen Rechtsstreitigkeiten wurden bekannt gegeben.

Wesentliche Erkenntnisse: Qualys kombiniert weiterhin zweistelliges Umsatzwachstum mit branchenführenden Margen und starker Cash-Generierung. Die Schwäche bei den abgegrenzten Erlösen und die gestiegenen Betriebsausgaben sollten beobachtet werden, aber die Liquidität und Aktienrückkäufe stützen den Gewinn je Aktie.

Positive
  • Double-digit revenue growth of 10.3% YoY and 10.0% YTD shows continued demand for the TruRisk platform.
  • Gross margin sustained at 82%+, highlighting high-leverage SaaS model.
  • EPS up 10% YoY aided by accretive share repurchases that reduced share count by 1%.
  • Operating cash flow increased to $143.4 m, funding operations and buybacks without debt.
  • Liquidity strength: $468 m in cash & marketable securities and no long-term debt.
Negative
  • Deferred revenue fell 4% sequentially, indicating softer near-term billings momentum.
  • Cash balance decreased $38 m due to $89 m in buybacks, reducing flexibility if macro weakens.
  • Operating expenses grew faster than revenue, trimming operating margin 100 bps YoY.
  • Other comprehensive loss of $4.2 m driven by FX hedges and rising hedge liabilities ($6.6 m).
  • Lease commitments increased by $30 m from HQ renewal, elevating long-term fixed costs.

Insights

TL;DR – Solid growth, stellar margins, accretive buybacks; slight bookings dip worth tracking.

Revenue and EPS beat prior-year comps by ~10%. 82% gross margin underscores platform scalability, while OCF conversion of 88% of net income signals healthy cash economics. Share count fell 1% YTD, adding ~3 ¢ to EPS. Liquidity of $468 m covers $255 m remaining buyback capacity and cap-ex. Deferred revenue contraction and opex growth suggest some demand normalization and heavier go-to-market spend, yet 31% operating margin remains well above SaaS peers. Valuation positives outweigh risks, so impact skewed modestly positive.

TL;DR – Rising commitments, FX volatility and revenue deferrals temper otherwise strong fundamentals.

HQ lease renewal extends obligations to 2034, boosting discounted lease liabilities to $55.3 m. Cash balance dipped 16% Q-o-Q, reflecting $89 m repurchases; continued aggressive buybacks could pressure liquidity if macro softens. Hedge liabilities climbed to $6.6 m, and OCI swung negative, evidencing currency exposure. Deferred revenue down $16 m sequentially may foreshadow slower billings. While no debt and sizeable investments mitigate risk, investors should watch cash deployment, booking trends and FX management. Net impact neutral.

Qualys (QLYS) evidenze del 10-Q del 2° trimestre 2025: I ricavi sono aumentati del 10,3% su base annua, raggiungendo 164,1 milioni di dollari, segnando il sesto trimestre consecutivo con una crescita a doppia cifra. Il margine lordo è rimasto solido al 82,4% (rispetto all'82,2% dell'anno precedente). L'utile operativo è cresciuto del 7%, arrivando a 51,4 milioni di dollari, mentre le spese operative sono aumentate del 13%, comprimendo leggermente il margine operativo al 31,3%. L'utile netto è salito dell'8% a 47,3 milioni di dollari; l'utile per azione diluito è aumentato del 10% a 1,29 dollari. Nel primo semestre 2025, i ricavi hanno raggiunto 324,0 milioni di dollari (+10%), l'utile netto 94,8 milioni (+13,6%) e il flusso di cassa operativo 143,4 milioni (+6%).

Bilancio e flusso di cassa: La liquidità e le disponibilità liquide sono diminuite di 38,2 milioni di dollari rispetto al trimestre precedente, attestandosi a 194,0 milioni; tuttavia, la liquidità totale (contanti + titoli negoziabili) è salita a 468,2 milioni. I ricavi differiti correnti sono scesi del 4% a 355,0 milioni, mentre le obbligazioni residue di prestazione ammontano a 433,2 milioni, con il 33% riconoscibile nella seconda metà del 2025. I riacquisti di azioni hanno totalizzato 89,5 milioni di dollari da inizio anno, riducendo le azioni in circolazione a 36,1 milioni; restano 254,6 milioni disponibili nell'autorizzazione da 1,4 miliardi.

Altri elementi: La remunerazione basata su azioni è stata di 18,0 milioni nel 2° trimestre (11% dei ricavi). L'OCI ha registrato una perdita di 4,2 milioni, principalmente dovuta alla valutazione delle coperture FX. L'estensione del contratto di locazione della sede centrale ha aggiunto 30,4 milioni di impegni futuri, aumentando gli asset e le passività da diritto d'uso. Non sono stati comunicati nuovi debiti né controversie rilevanti.

Punti chiave: Qualys continua a combinare una crescita a doppia cifra dei ricavi con margini leader nel settore e una solida generazione di cassa. La debolezza nei ricavi differiti e l’aumento delle spese operative meritano attenzione, ma la liquidità e i riacquisti supportano la dinamica positiva dell’utile per azione.

Aspectos destacados del 10-Q del 2T-25 de Qualys (QLYS): Los ingresos aumentaron un 10,3% interanual hasta 164,1 millones de dólares, marcando el sexto trimestre consecutivo con un crecimiento de dos dígitos. El margen bruto se mantuvo sólido en 82,4% (frente al 82,2% del año anterior). El ingreso operativo creció un 7% hasta 51,4 millones de dólares, aunque los gastos operativos aumentaron un 13%, comprimiendo ligeramente el margen operativo al 31,3%. La utilidad neta avanzó un 8% hasta 47,3 millones; las ganancias diluidas por acción subieron un 10% hasta 1,29 dólares. En el primer semestre de 2025, los ingresos alcanzaron 324,0 millones (+10%), la utilidad neta 94,8 millones (+13,6%) y el flujo de caja operativo 143,4 millones (+6%).

Balance y flujo de caja: El efectivo y equivalentes disminuyeron 38,2 millones secuencialmente hasta 194,0 millones; sin embargo, la liquidez total (efectivo + valores negociables) aumentó a 468,2 millones. Los ingresos diferidos corrientes cayeron un 4% a 355,0 millones, mientras que las obligaciones de desempeño restantes totalizan 433,2 millones, con un 33% reconocible en el segundo semestre de 2025. Las recompras de acciones sumaron 89,5 millones en lo que va del año, reduciendo las acciones en circulación a 36,1 millones; quedan 254,6 millones disponibles bajo la autorización de 1,4 mil millones.

Otros aspectos: La compensación basada en acciones fue de 18,0 millones en el 2T (11% de los ingresos). El OCI pasó a una pérdida de 4,2 millones, principalmente por la valoración de coberturas cambiarias. Una extensión del contrato de arrendamiento de la sede central añadió 30,4 millones en compromisos futuros, aumentando activos y pasivos por derecho de uso. No se divulgaron nuevas deudas ni litigios materiales.

Conclusiones clave: Qualys sigue combinando un crecimiento de ingresos de dos dígitos con márgenes líderes en la industria y fuerte generación de efectivo. La debilidad en ingresos diferidos y el aumento del gasto operativo merecen seguimiento, pero la liquidez y las recompras respaldan el impulso en las ganancias por acción.

Qualys (QLYS) 2025년 2분기 10-Q 주요 내용: 매출이 전년 대비 10.3% 증가한 1억 6,410만 달러를 기록하며 6분기 연속 두 자릿수 성장세를 이어갔습니다. 총 이익률은 82.4%로 견고하게 유지되었습니다(전년 동기 82.2%). 영업이익은 7% 증가한 5,140만 달러였으나, 영업비용이 13% 증가해 영업이익률은 다소 하락한 31.3%를 기록했습니다. 순이익은 8% 증가한 4,730만 달러, 희석주당순이익(EPS)은 10% 상승한 1.29달러였습니다. 2025년 상반기 매출은 3억 2,400만 달러(+10%), 순이익은 9,480만 달러(+13.6%), 영업현금흐름은 1억 4,340만 달러(+6%)였습니다.

재무상태표 및 현금흐름: 현금 및 현금성 자산은 전분기 대비 3,820만 달러 감소한 1억 9,400만 달러였으나, 총 유동성(현금 + 시장성 증권)은 4억 6,820만 달러로 증가했습니다. 현재 이연수익은 4% 감소한 3억 5,500만 달러이며, 남은 이행 의무는 총 4억 3,320만 달러로 이 중 33%는 2025년 하반기에 인식될 예정입니다. 올해 들어 자사주 매입은 8,950만 달러에 달하며, 유통 주식 수는 3,610만 주로 감소했습니다. 14억 달러 한도 내에서 2억 5,460만 달러가 남아있습니다.

기타 항목: 2분기 주식기반보상은 1,800만 달러(매출의 11%)였습니다. 기타포괄손익(OCI)은 주로 외환 헤지 평가손실로 420만 달러 손실 전환되었습니다. 본사 임대 연장으로 향후 약속금액이 3,040만 달러 추가되어 사용권자산 및 임대부채가 증가했습니다. 신규 부채나 주요 소송은 없었습니다.

주요 시사점: Qualys는 두 자릿수 매출 성장과 업계 선도 마진, 강력한 현금 창출을 지속적으로 조합하고 있습니다. 이연수익의 약세와 운영 비용 증가에 주의가 필요하지만, 유동성과 자사주 매입이 EPS 성장 모멘텀을 뒷받침하고 있습니다.

Faits marquants du 10-Q du 2e trimestre 2025 de Qualys (QLYS) : Le chiffre d'affaires a augmenté de 10,3 % en glissement annuel pour atteindre 164,1 millions de dollars, marquant le sixième trimestre consécutif de croissance à deux chiffres. La marge brute est restée solide à 82,4 % (contre 82,2 % il y a un an). Le résultat d'exploitation a progressé de 7 % pour atteindre 51,4 millions de dollars, mais les charges d'exploitation ont augmenté de 13 %, comprimant légèrement la marge opérationnelle à 31,3 %. Le résultat net a augmenté de 8 % pour atteindre 47,3 millions de dollars ; le BPA dilué a grimpé de 10 % à 1,29 dollar. Pour le premier semestre 2025, le chiffre d'affaires s'est élevé à 324,0 millions (+10 %), le résultat net à 94,8 millions (+13,6 %) et les flux de trésorerie opérationnels à 143,4 millions (+6 %).

Bilan et flux de trésorerie : La trésorerie et les équivalents de trésorerie ont diminué de 38,2 millions séquentiellement pour atteindre 194,0 millions ; toutefois, la liquidité totale (trésorerie + titres négociables) a augmenté pour atteindre 468,2 millions. Les revenus différés courants ont chuté de 4 % à 355,0 millions, tandis que les obligations de performance restantes totalisent 433,2 millions, dont 33 % sont reconnaissables au second semestre 2025. Les rachats d'actions ont totalisé 89,5 millions depuis le début de l'année, réduisant le nombre d'actions en circulation à 36,1 millions ; 254,6 millions restent disponibles dans le cadre de l'autorisation de 1,4 milliard.

Autres éléments : La rémunération à base d'actions s'est élevée à 18,0 millions au 2e trimestre (11 % du chiffre d'affaires). Les autres éléments du résultat global (OCI) sont passés à une perte de 4,2 millions, principalement en raison de la valorisation des couvertures de change. Une extension du bail du siège social a ajouté 30,4 millions d'engagements futurs, augmentant les actifs au titre du droit d’usage et les passifs locatifs. Aucune nouvelle dette ni litige important n'a été divulgué.

Points clés : Qualys continue d’allier une croissance à deux chiffres du chiffre d’affaires à des marges leaders sur le marché et une forte génération de trésorerie. La faiblesse des revenus différés et l’augmentation des dépenses opérationnelles méritent une surveillance, mais la liquidité et les rachats d’actions soutiennent la dynamique du BPA.

Qualys (QLYS) Highlights aus dem 10-Q für Q2-25: Der Umsatz stieg im Jahresvergleich um 10,3 % auf 164,1 Mio. USD und verzeichnet damit das sechste Quartal in Folge mit zweistelligem Wachstum. Die Bruttomarge blieb mit 82,4 % robust (vor einem Jahr 82,2 %). Das Betriebsergebnis wuchs um 7 % auf 51,4 Mio. USD, während die Betriebskosten um 13 % stiegen, was die operative Marge leicht auf 31,3 % drückte. Der Nettogewinn stieg um 8 % auf 47,3 Mio. USD; das verwässerte Ergebnis je Aktie kletterte um 10 % auf 1,29 USD. Für das erste Halbjahr 2025 erreichten die Umsätze 324,0 Mio. USD (+10 %), der Nettogewinn 94,8 Mio. USD (+13,6 %) und der operative Cashflow 143,4 Mio. USD (+6 %).

Bilanz & Cashflow: Zahlungsmittel und Zahlungsmitteläquivalente sanken im Quartalsvergleich um 38,2 Mio. USD auf 194,0 Mio. USD; die Gesamtlquidität (Barmittel + handelbare Wertpapiere) stieg jedoch auf 468,2 Mio. USD. Die kurzfristigen abgegrenzten Erlöse fielen um 4 % auf 355,0 Mio. USD, während die verbleibenden Leistungsverpflichtungen insgesamt 433,2 Mio. USD betragen, von denen 33 % im zweiten Halbjahr 2025 erkennbar sind. Aktienrückkäufe beliefen sich seit Jahresbeginn auf 89,5 Mio. USD und reduzierten die ausstehenden Aktien auf 36,1 Mio.; unter der 1,4 Mrd. USD-Autorisierung verbleiben 254,6 Mio. USD.

Sonstiges: Aktienbasierte Vergütungen betrugen im 2. Quartal 18,0 Mio. USD (11 % der Umsätze). Das sonstige Ergebnis (OCI) drehte in einen Verlust von 4,2 Mio. USD, hauptsächlich aufgrund der Bewertung von Devisenabsicherungen. Eine Verlängerung des Hauptsitzmietvertrags fügte zukünftige Verpflichtungen in Höhe von 30,4 Mio. USD hinzu, was die Nutzungsrechte und Leasingverbindlichkeiten erhöhte. Keine neuen Schulden oder wesentlichen Rechtsstreitigkeiten wurden bekannt gegeben.

Wesentliche Erkenntnisse: Qualys kombiniert weiterhin zweistelliges Umsatzwachstum mit branchenführenden Margen und starker Cash-Generierung. Die Schwäche bei den abgegrenzten Erlösen und die gestiegenen Betriebsausgaben sollten beobachtet werden, aber die Liquidität und Aktienrückkäufe stützen den Gewinn je Aktie.

As filed with the Securities and Exchange Commission on August 5, 2025

Registration No. 333-262083

Registration No. 333-270711

Registration No. 333-278226

Registration No. 333-285766

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT TO

Form S-8 Registration No. 333-262083

Form S-8 Registration No. 333-270711

Form S-8 Registration No. 333-278226

Form S-8 Registration No. 333-285766

UNDER

THE SECURITIES ACT OF 1933

 

 

VIGIL NEUROSCIENCE, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   83-1880494

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

100 Forge Road, Suite 700

Watertown, Massachusetts 02472

(857) 254-4445

(Address of Principal Executive Offices) (Zip Code)

Vigil Neuroscience, Inc. Amended and Restated 2020 Equity Incentive Plan

Vigil Neuroscience, Inc. 2021 Stock Option and Incentive Plan

Vigil Neuroscience, Inc. 2021 Employee Stock Purchase Plan

Vigil Neuroscience, Inc. Non-Qualified Stock Option Agreement for Inducement Award

(Full title of the plans)

Ivana Magovčević-Liebisch

Chief Executive Officer

Vigil Neuroscience, Inc.

100 Forge Road, Suite 700

Watertown, Massachusetts 02472

(857) 254-4445

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

 

 

Copies to:

Kingsley L. Taft, Esq.

Jacqueline Mercier, Esq.

Gabriela Morales-Rivera, Esq.

Goodwin Procter LLP

100 Northern Avenue

Boston, MA 02210

(617) 570-1000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


DEREGISTRATION OF SECURITIES

These Post-Effective Amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Vigil Neuroscience, Inc., a Delaware corporation (the “Registrant”):

 

   

Registration Statement No.  333-262083, filed with the SEC on January 10, 2022, pertaining to the registration of 3,086,742 shares of common stock, par value $0.0001 per share (“Common Stock”), of the Registrant reserved for issuance under the Vigil Neuroscience, Inc. Amended and Restated 2020 Equity Incentive Plan, 3,145,281 shares of Common Stock reserved for issuance under the Vigil Neuroscience, Inc. 2021 Stock Option and Incentive Plan (the “2021 Plan”) and 286,127 shares of Common Stock reserved for issuance under the Vigil Neuroscience, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”);

 

   

Registration Statement No.  333-270711, filed with the SEC on March 21, 2023, pertaining to the registration of an additional 1,781,016 shares of Common Stock reserved for issuance under the 2021 Plan and 286,127 shares of Common Stock reserved for issuance under the ESPP;

 

   

Registration Statement No.  333-278226, filed with the SEC on March 26, 2024, pertaining to the registration of an additional 1,794,235 shares of Common Stock reserved for issuance under the 2021 Plan and 330,000 shares of Common Stock issuable under an inducement stock option award granted on March 18, 2024; and

 

   

Registration Statement No.  333-285766, filed with the SEC on March 13, 2025, pertaining to the registration of an additional 2,044,338 shares of Common Stock reserved for issuance under the 2021 Plan.

On August 5, 2025, pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of May 21, 2025, by and among the Registrant, Sanofi, a French société anonyme (“Sanofi”), and Vesper Acquisition Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Sanofi (“Merger Sub”), Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant surviving the Merger as a wholly-owned subsidiary of Sanofi.

As a result of the Merger, the Registrant has terminated, as of the date hereof, any and all offerings of its securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, by filing these Post-Effective Amendments, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statements, if any, as of the date hereof, and the Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Massachusetts, on August 5, 2025.

 

VIGIL NEUROSCIENCE, INC.
By:  

/s/ Michael Tolpa

  Name: Michael Tolpa
  Title: Treasurer

No other person is required to sign these Post-Effective Amendments to the Registration Statements on Form S-8 in reliance on Rule 478 of the Securities Act of 1933, as amended.

FAQ

How much did Qualys (QLYS) grow revenue in Q2 2025?

Revenue rose 10.3% year-over-year to $164.1 million.

What were QLYS diluted earnings per share for Q2 2025?

Diluted EPS was $1.29, up from $1.17 in Q2 2024.

What is Qualys’ current gross margin?

Gross margin remained high at 82.4% for the quarter.

How much cash does Qualys have after Q2 2025?

Cash and cash equivalents totaled $194 million; total liquidity including securities was $468 million.

How large is the remaining share repurchase authorization?

Qualys still has $254.6 million available under its $1.4 billion buyback program.

Why did deferred revenue decline in the quarter?

Current deferred revenue fell to $355 million (-$16 million QoQ), suggesting lighter new billings or shorter contract durations.

Did Qualys take on any new debt during the period?

No. The company remains debt-free according to the 10-Q.
Vigil Neuroscience, Inc.

NASDAQ:VIGL

VIGL Rankings

VIGL Latest News

VIGL Latest SEC Filings

VIGL Stock Data

375.71M
44.24M
18.16%
67.2%
0.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WATERTOWN